Research - OGXI is a speculative, micro-cap oncology company – now, essentially a call option with multiple shots on goal. $60 million in cash/equivalents provide a backdrop … Continue Reading
PremiumResearch - Intercept (ICPT) jumped to the top of many watchlists when a drug for liver diseases showed success in a P2 trial. Here's another, cheaper idea.
Read nowInterviews - A recent FDA bulletin puts the success rate of Phase II clinical trials at just 18%, 50% in Phase III, citing insufficient efficacy and safety concerns as the … Continue Reading
Read nowResearch - The American Society of Clinical Oncology (ASCO) annual meeting is right around the corner, and healthcare investors will have a close eye on ASCO for … Continue Reading
Read nowInsights - AVEO has lost more than 90% of its market valuation in the last 21 months; another of PropThink’s “Drugs that Disappointed in 2013.” In February, AVEO … Continue Reading
Read nowInsights - A look at what caused Infinity Pharma's (INFI) spectacular rise and fall in 2013, and the road ahead.
Read nowInsights - Though 2013 looked to be a good year for Affymax (AFFY), it quickly spiraled downward when the Cupertino, CA-based biotech and its partner, Japanese drug … Continue Reading
Read now
